Shares of Akero Therapeutics (NASDAQ:AKRO) have earned an average broker rating score of 1.00 (Strong Buy) from the four brokers that provide coverage for the stock, Zacks Investment Research reports. Four equities research analysts have rated the stock with a strong buy recommendation.
Brokers have set a twelve-month consensus price objective of $31.25 for the company and are predicting that the company will post ($0.36) EPS for the current quarter, according to Zacks. Zacks has also assigned Akero Therapeutics an industry rank of 51 out of 256 based on the ratings given to related companies.
AKRO has been the subject of a number of research analyst reports. Jefferies Financial Group set a $189.00 price target on shares of salesforce.com and gave the company a “buy” rating in a report on Monday, July 15th. Roth Capital reissued a “buy” rating on shares of Coeur Mining in a report on Monday, July 15th. JPMorgan Chase & Co. reissued a “sell” rating and issued a $18.00 price target on shares of ABB in a report on Monday, July 15th. Finally, Evercore ISI initiated coverage on shares of Akero Therapeutics in a report on Monday, July 15th. They issued an “outperform” rating and a $35.00 price target for the company.
In other news, Director Seth Loring Harrison acquired 900,000 shares of Akero Therapeutics stock in a transaction on Monday, June 24th. The stock was bought at an average cost of $16.00 per share, with a total value of $14,400,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Global Strategic Fund I. Venbio acquired 250,000 shares of Akero Therapeutics stock in a transaction on Monday, June 24th. The shares were purchased at an average cost of $16.00 per share, with a total value of $4,000,000.00. The disclosure for this purchase can be found here.
Shares of NASDAQ AKRO opened at $20.78 on Tuesday. Akero Therapeutics has a twelve month low of $16.06 and a twelve month high of $22.91.
Akero Therapeutics Company Profile
Akero Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development and commercialization of transformative treatments for serious metabolic diseases with high unmet medical need. Its lead product candidate is AKR-001, which completed Phase Ib clinical trial for the treatment of non-alcoholic steatohepatitis disease.
See Also: Beta
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.